1. Home
  2. SNY vs REGN Comparison

SNY vs REGN Comparison

Compare SNY & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sanofi ADS

SNY

Sanofi ADS

N/A

Current Price

$46.64

Market Cap

95.7B

Sector

Health Care

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$919.82

Market Cap

84.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNY
REGN
Founded
1994
1988
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.7B
84.3B
IPO Year
2001
1995

Fundamental Metrics

Financial Performance
Metric
SNY
REGN
Price
$46.64
$919.82
Analyst Decision
Buy
Buy
Analyst Count
11
28
Target Price
$54.92
★ $991.00
AVG Volume (30 Days)
★ 4.2M
869.8K
Earning Date
10-30-2026
10-30-2026
Dividend Yield
★ 5.25%
0.41%
EPS Growth
N/A
★ 8.19
EPS
N/A
★ 37.37
Revenue
N/A
★ $5,872,227,000.00
Revenue This Year
$3.97
$31.18
Revenue Next Year
$6.77
$7.19
P/E Ratio
★ $6.14
$24.71
Revenue Growth
N/A
★ 20.82
52 Week Low
$39.07
$591.52
52 Week High
$50.61
$991.73

Technical Indicators

Market Signals
Indicator
SNY
REGN
Relative Strength Index (RSI) 57.70 57.41
Support Level $45.95 $735.26
Resistance Level $48.57 $986.64
Average True Range (ATR) 0.86 32.57
MACD -0.20 -4.43
Stochastic Oscillator 40.49 32.58

Price Performance

Historical Comparison
SNY
REGN

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: